| Alan Clark Bean, MD | |
|
75 Weston Farm Road, Harrison, ME 04040 | |
| (207) 583-4008 | |
| (207) 583-9008 |
| Full Name | Alan Clark Bean |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 75 Weston Farm Road, Harrison, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841411337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 012730 (Maine) | Primary |
| Entity Name | American Current Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053680876 PECOS PAC ID: 9739260019 Enrollment ID: O20090402000545 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
Royal Philips Electronics announced today its launch of the Philips InnerCool RTx Endovascular System for cooling and warming, which provides advanced whole body temperature modulation therapy in a closed-loop system from the inside out. The InnerCool RTx is a high-performance system that can rapidly raise and lower the body temperature of certain non-paralyzed, awake patients of all sizes in the intensive care setting.
Quark Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy ("NAION") with the Company's ocular neuroprotectant QPI-1007.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan Clark Bean, MD 75 Weston Farm Road, Harrison, ME 04040 Ph: (207) 583-2923 | Alan Clark Bean, MD 75 Weston Farm Road, Harrison, ME 04040 Ph: (207) 583-4008 |
News Archive
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
Royal Philips Electronics announced today its launch of the Philips InnerCool RTx Endovascular System for cooling and warming, which provides advanced whole body temperature modulation therapy in a closed-loop system from the inside out. The InnerCool RTx is a high-performance system that can rapidly raise and lower the body temperature of certain non-paralyzed, awake patients of all sizes in the intensive care setting.
Quark Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy ("NAION") with the Company's ocular neuroprotectant QPI-1007.
› Verified 3 days ago